A
Anna-Leena Sirén
Researcher at University of Würzburg
Publications - 77
Citations - 6581
Anna-Leena Sirén is an academic researcher from University of Würzburg. The author has contributed to research in topics: Neuroprotection & Erythropoietin. The author has an hindex of 35, co-authored 73 publications receiving 6171 citations. Previous affiliations of Anna-Leena Sirén include Max Planck Society.
Papers
More filters
Journal ArticleDOI
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
Anna-Leena Sirén,Maddalena Fratelli,Michael Brines,Christoph G. Goemans,Simona Casagrande,Piotr Lewczuk,Sonja Keenan,Christoph H. Gleiter,Claudio Pasquali,Annalisa Capobianco,Tiziana Mennini,Rolf Heumann,Anthony Cerami,Hannelore Ehrenreich,Pietro Ghezzi +14 more
TL;DR: Data suggest that inhibition of neuronal apoptosis underlies short latency protective effects of EPO after cerebral ischemia and other brain injuries, and the neurotrophic actions suggest there may be longer-latency effects as well.
Journal ArticleDOI
Erythropoietin therapy for acute stroke is both safe and beneficial.
Hannelore Ehrenreich,Martin Hasselblatt,Christoph Dembowski,Lukas Cepek,Piotr Lewczuk,Michael Stiefel,Hans-Heino Rustenbeck,Norbert Breiter,Sonja Jacob,Friederike Knerlich,Matthias Bohn,Wolfgang Poser,Eckart Rüther,Michael M. Kochen,Olaf Gefeller,Christoph H. Gleiter,Thomas C. Wessel,Marc De Ryck,Loretta M. Itri,H W Prange,Anthony Cerami,Michael Brines,Anna-Leena Sirén +22 more
TL;DR: Intravenous high-dose rhEPO is well tolerated in acute ischemic stroke and associated with an improvement in clinical outcome at 1 month, and analysis of covariance controlled for these two variables indicated thatrhEPO treatment was associated with a improvement in follow-up and outcome scales.
Journal ArticleDOI
Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain
Anna-Leena Sirén,Friederike Knerlich,Wolfgang Poser,Christoph H. Gleiter,Wolfgang Brück,Hannelore Ehrenreich +5 more
TL;DR: The pronounced up-regulation of EPO/EPOR in human ischemic/hypoxic brains underlines their role as an endogenous neuroprotective system and suggests a novel therapeutic potential in cerebrovascular disease for EPO, a clinically well-characterized and safe compound.
Journal ArticleDOI
Reduced oxidative damage in ALS by high-dose enteral melatonin treatment.
Jochen H. Weishaupt,Claudia Bartels,Esther Polking,Jeannine Dietrich,Gundula Rohde,Burkhard Poeggeler,Nina Mertens,Swetlana Sperling,Matthias Bohn,Gerald Hüther,Armin Schneider,Bach Alfred,Anna-Leena Sirén,Rüdiger Hardeland,Mathias Bähr,Klaus-Armin Nave,Hannelore Ehrenreich +16 more
TL;DR: It is found that melatonin attenuates glutamate‐induced cell death of cultured motoneurons and suggests that high‐dose melatonin is suitable for clinical trials aimed at neuroprotection through antioxidation in ALS.
Journal ArticleDOI
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.
Hannelore Ehrenreich,Dunja Hinze-Selch,Sabina Stawicki,Carlotta Aust,S. Knolle-Veentjer,S. Wilms,G. Heinz,S. Erdag,H. Jahn,H. Jahn,Detlef Degner,M. Ritzen,A. Mohr,Michael Wagner,Udo Schneider,Matthias Bohn,M. Huber,A. Czernik,T. Pollmacher,Wolfgang Maier,Anna-Leena Sirén,Joachim Klosterkötter,Peter Falkai,E. Rüther,Josef B. Aldenhoff,Henning Krampe +25 more
TL;DR: Patients receiving rhEPO showed a significant improvement over placebo patients in schizophrenia-related cognitive performance (RBANS subtests, WCST-64), but no effects on psychopathology or social functioning.